Answers are grounded in this paper and cite their sources.
Colorectal cancer (CRC) may develop through the conventional adenoma-to-carcinoma sequence or alternative routes of carcinogenesis, accompanied by changes in epithelial cell states and remodeling of the tumor microenvironment, yet its core driving mechanisms and therapeutic options remain unclear. This study integrated single-cell, bulk transcriptomic, and spatial transcriptomic datasets for comprehensive bioinformatics analyses, followed by validation in CRC cells and clinical samples using immunohistochemistry. Epithelial cells showed the most pronounced transcriptional and cell-communication remodeling during adenoma-to-carcinoma progression, with marked expansion of tumor-related subpopulations including tumor epithelial cells, stem-like tumor cells, and proliferating tumor cells. Multi-omics integration identified tissue inhibitor of metalloproteinase 1 (TIMP1) and claudin-23 (CLDN23) as core genes closely linked to inflammatory, immune, and metabolic pathways. Ruxolitinib was predicted to target the TIMP1/CLDN23 regulatory network, and in vitro experiments confirmed that it downregulated TIMP1, upregulated CLDN23, and suppressed CRC cell proliferation. Functional assays further showed that TIMP1 promoted while CLDN23 inhibited CRC cell proliferation and migration, and that the two genes may act cooperatively through their shared downstream molecule selenium-binding protein 1 (SELENBP1). These findings suggest an epithelial-centered mechanism of adenoma-to-CRC progression, identify TIMP1 and CLDN23 as molecules with diagnostic, prognostic, and therapeutic potential, and provide preliminary support for repurposing Ruxolitinib in CRC.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: